{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:12:48Z","timestamp":1789783968148,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["10.13039\/10000995"],"award-info":[{"award-number":["10.13039\/10000995"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-51994-3","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T05:02:40Z","timestamp":1725339760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Towards clinically relevant dose ratios for Cabamiquine and Pyronaridine combination using P. falciparum field isolate data"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1537-9087","authenticated-orcid":false,"given":"Mohamed","family":"Maiga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9087-8439","authenticated-orcid":false,"given":"Laurent","family":"Dembele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perrine","family":"Courlet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Khandelwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7739-4437","authenticated-orcid":false,"given":"Antoine","family":"Dara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanta","family":"Sogore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ousmaila","family":"Diakit\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatoumata O.","family":"Maiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4925-6093","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Dao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8390-1431","authenticated-orcid":false,"given":"Sekou","family":"Sissoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yacouba","family":"Barre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siaka","family":"Goita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4268-8857","authenticated-orcid":false,"given":"Mahamadou","family":"Diakite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seidina A. S.","family":"Diakite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0062-2283","authenticated-orcid":false,"given":"Abdoulaye A.","family":"Djimde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Oeuvray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5654-8919","authenticated-orcid":false,"given":"Thomas","family":"Spangenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8773-4845","authenticated-orcid":false,"given":"Sebastian G.","family":"Wicha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9610-2962","authenticated-orcid":false,"given":"Claudia","family":"Demarta-Gatsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"key":"51994_CR1","unstructured":"World Health Organization. WHO Malaria Report 2019. Malaria Report 2019 (WHO, 2019)."},{"key":"51994_CR2","unstructured":"World Health Organization. WHO Malaria Report 2022 (WHO, 2022)."},{"key":"51994_CR3","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","volume":"26","author":"A Uwimana","year":"2020","unstructured":"Uwimana, A. et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat. Med. 26, 1602\u20131608 (2020).","journal-title":"Nat. Med."},{"key":"51994_CR4","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/S1473-3099(19)30391-3","volume":"19","author":"RW van der Pluijm","year":"2019","unstructured":"van der Pluijm, R. W. et al. Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infect. Dis. 19, 952\u2013961 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"51994_CR5","doi-asserted-by":"publisher","first-page":"e1010317","DOI":"10.1371\/journal.pcbi.1010317","volume":"18","author":"JA Flegg","year":"2022","unstructured":"Flegg, J. A. et al. Spatiotemporal spread of Plasmodium falciparum mutations for resistance to sulfadoxine-pyrimethamine across Africa, 1990\u20132020. PLoS Comput. Biol. 18, e1010317 (2022).","journal-title":"PLoS Comput. Biol."},{"key":"51994_CR6","doi-asserted-by":"crossref","unstructured":"Singh Sidhu, A. B., Verdier-Pinard, D. & Fidock, D. A. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 298, 210\u2013213 (2002).","DOI":"10.1126\/science.1074045"},{"key":"51994_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature14451","volume":"522","author":"B Baraga\u00f1a","year":"2015","unstructured":"Baraga\u00f1a, B. et al. A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature 522, 315\u2013320 (2015).","journal-title":"Nature"},{"key":"51994_CR8","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1093\/jac\/dkad260","volume":"78","author":"W-Y Chu","year":"2023","unstructured":"Chu, W.-Y. & Dorlo, T. P. C. Pyronaridine: a review of its clinical pharmacology in the treatment of malaria. J. Antimicrob. Chemother. 78, 2406\u20132418 (2023).","journal-title":"J. Antimicrob. Chemother."},{"key":"51994_CR9","doi-asserted-by":"crossref","unstructured":"Kurth, F., B\u00e9lard, S., Basra, A. & Ramharter, M. Pyronaridine-artesunate combination therapy for the treatment of malaria. Curr. Opin. Infect. Dis. 24, 564\u2013569 (2011).","DOI":"10.1097\/QCO.0b013e32834cabdb"},{"key":"51994_CR10","doi-asserted-by":"crossref","unstructured":"Rottmann, M. et al. Preclinical antimalarial combination study of M5717, a Plasmodium falciparum elongation factor 2 inhibitor, and pyronaridine, a hemozoin formation inhibitor. Antimicrob. Agents Chemother. 64, 10\u20131128 (2020).","DOI":"10.1128\/AAC.02181-19"},{"key":"51994_CR11","doi-asserted-by":"publisher","first-page":"4533","DOI":"10.1128\/AAC.00519-09","volume":"53","author":"MB Jime\u0301nez-Di\u0301az","year":"2009","unstructured":"Jime\u0301nez-Di\u0301az, M. B. et al. Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes. Antimicrob. Agents Chemother. 53, 4533\u20134536 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"51994_CR12","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/S1473-3099(21)00252-8","volume":"21","author":"JS McCarthy","year":"2021","unstructured":"McCarthy, J. S. et al. Safety, pharmacokinetics, and antimalarial activity of the novel Plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection stu. Lancet Infect. Dis. 21, 1713\u20131724 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"51994_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-1053-0","volume":"15","author":"J White","year":"2016","unstructured":"White, J. et al. In vitro adaptation of Plasmodium falciparum reveal variations in cultivability. Malar. J. 15, 33 (2016).","journal-title":"Malar. J."},{"key":"51994_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-1021-8","volume":"14","author":"S Chaorattanakawee","year":"2015","unstructured":"Chaorattanakawee, S. et al. Attenuation of Plasmodium falciparum in vitro drug resistance phenotype following culture adaptation compared to fresh clinical isolates in Cambodia. Malar. J. 14, 486 (2015).","journal-title":"Malar. J."},{"key":"51994_CR15","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.pt.2020.08.008","volume":"36","author":"AC Brown","year":"2020","unstructured":"Brown, A. C. & Guler, J. L. From circulation to cultivation: Plasmodium in vivo versus in vitro. Trends Parasitol. 36, 914\u2013926 (2020).","journal-title":"Trends Parasitol."},{"key":"51994_CR16","doi-asserted-by":"publisher","first-page":"e1010375","DOI":"10.1371\/journal.ppat.1010375","volume":"18","author":"L Piel","year":"2022","unstructured":"Piel, L. et al. Experimental evolution links posttranscriptional regulation to Leishmania fitness gain. PLoS Pathog. 18, e1010375 (2022).","journal-title":"PLoS Pathog."},{"key":"51994_CR17","doi-asserted-by":"crossref","unstructured":"Lee, H. J. et al. Transcriptomic studies of malaria: a paradigm for investigation of systemic host-pathogen interactions. Microbiol. Mol. Biol. Rev. 82, 10\u20131128 (2018).","DOI":"10.1128\/MMBR.00071-17"},{"key":"51994_CR18","doi-asserted-by":"crossref","unstructured":"Wicha, S. G. et al. New in vitro interaction-parasite reduction ratio assay for early derisk in clinical development of antimalarial combinations. Antimicrob. Agents Chemother. 66, e00556-22 (2022).","DOI":"10.1128\/aac.00556-22"},{"key":"51994_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02440-6","volume":"7","author":"L Dembele","year":"2017","unstructured":"Dembele, L. et al. The Plasmodium PI(4)K inhibitor KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites. Sci. Rep. 7, 2325 (2017).","journal-title":"Sci. Rep."},{"key":"51994_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1208\/s12248-018-0239-0","volume":"20","author":"C Chen","year":"2018","unstructured":"Chen, C., Wicha, S. G., Nordgren, R. & Simonsson, U. S. H. Comparisons of analysis methods for assessment of pharmacodynamic interactions including design recommendations. AAPS J. 20, 77 (2018).","journal-title":"AAPS J."},{"key":"51994_CR21","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1007\/s11095-015-1632-3","volume":"32","author":"SG Wicha","year":"2015","unstructured":"Wicha, S. G., Kees, M. G., Kuss, J. & Kloft, C. Pharmacodynamic and response surface analysis of linezolid or vancomycin combined with meropenem against Staphylococcus aureus. Pharm. Res. 32, 2410\u20132418 (2015).","journal-title":"Pharm. Res."},{"key":"51994_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01929-y","volume":"8","author":"SG Wicha","year":"2017","unstructured":"Wicha, S. G., Chen, C., Clewe, O. & Simonsson, U. S. H. A general pharmacodynamic interaction model identifies perpetrators and victims in drug interactions. Nat. Commun. 8, 2129 (2017).","journal-title":"Nat. Commun."},{"key":"51994_CR23","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1124\/pr.111.005769","volume":"65","author":"EI Nielsen","year":"2013","unstructured":"Nielsen, E. I. & Friberg, L. E. Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. Pharmacol. Rev. 65, 1053\u20131090 (2013).","journal-title":"Pharmacol. Rev."},{"key":"51994_CR24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/jcph.2128","volume":"63","author":"RA Pearson","year":"2023","unstructured":"Pearson, R. A., Wicha, S. G. & Okour, M. Drug combination modeling: methods and applications in drug development. J. Clin. Pharmacol. 63, 151\u2013165 (2023).","journal-title":"J. Clin. Pharmacol."},{"key":"51994_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand, M., Hooker, A. C., Wallin, J. E. & Karlsson, M. O. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 13, 143\u2013151 (2011).","journal-title":"AAPS J."},{"key":"51994_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40974-8","volume":"14","author":"E Stadler","year":"2023","unstructured":"Stadler, E. et al. Propensity of selecting mutant parasites for the antimalarial drug cabamiquine. Nat. Commun. 14, 5205 (2023).","journal-title":"Nat. Commun."},{"key":"51994_CR27","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00891-23","volume":"67","author":"P Courlet","year":"2023","unstructured":"Courlet, P., Wilkins, J. J., Oeuvray, C., Gao, W. & Khandelwal, A. Semi-mechanistic population pharmacokinetic\/pharmacodynamic modeling of a Plasmodium elongation factor 2 inhibitor cabamiquine for prevention and cure of malaria. Antimicrob. Agents Chemother. 67, e0089123 (2023).","journal-title":"Antimicrob. Agents Chemother."},{"key":"51994_CR28","unstructured":"Wattanavijitkul, T. Population Pharmacokinetics of Pyronaridine in the Treatment of Malaria (University of Iowa, 2010)."},{"key":"51994_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0962-2","volume":"14","author":"M Linares","year":"2015","unstructured":"Linares, M. et al. Identifying rapidly parasiticidal anti-malarial drugs using a simple and reliable in vitro parasite viability fast assay. Malar. J. 14, 441 (2015).","journal-title":"Malar. J."},{"key":"51994_CR30","doi-asserted-by":"publisher","first-page":"e30949","DOI":"10.1371\/journal.pone.0030949","volume":"7","author":"LM Sanz","year":"2012","unstructured":"Sanz, L. M. et al. P. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-action. PLoS ONE 7, e30949 (2012).","journal-title":"PLoS ONE"},{"key":"51994_CR31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/ph16020163","volume":"16","author":"A Walz","year":"2023","unstructured":"Walz, A. et al. The parasite reduction ratio (PRR) assay version 2: standardized assessment of Plasmodium falciparum viability after antimalarial treatment in vitro. Pharmaceuticals 16, 163 (2023).","journal-title":"Pharmaceuticals"},{"key":"51994_CR32","first-page":"963","volume":"221","author":"LF Wockner","year":"2020","unstructured":"Wockner, L. F. et al. Growth rate of Plasmodium falciparum: analysis of parasite growth data from malaria volunteer infection studies. J. Infect. Dis. 221, 963\u2013972 (2020).","journal-title":"J. Infect. Dis."},{"key":"51994_CR33","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1128\/AAC.45.11.3175-3181.2001","volume":"45","author":"CS Gavigan","year":"2001","unstructured":"Gavigan, C. S., Machado, S. G., Dalton, J. P. & Bell, A. Analysis of antimalarial synergy between bestatin and endoprotease inhibitors using statistical response-surface modelling. Antimicrob. Agents Chemother. 45, 3175\u20133181 (2001).","journal-title":"Antimicrob. Agents Chemother."},{"key":"51994_CR34","doi-asserted-by":"publisher","first-page":"e1009172","DOI":"10.1371\/journal.ppat.1009172","volume":"17","author":"R Roemhild","year":"2021","unstructured":"Roemhild, R. & Andersson, D. I. Mechanisms and therapeutic potential of collateral sensitivity to antibiotics. PLoS Pathog. 17, e1009172 (2021).","journal-title":"PLoS Pathog."},{"key":"51994_CR35","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.actatropica.2005.04.005","volume":"94","author":"D Walliker","year":"2005","unstructured":"Walliker, D., Hunt, P. & Babiker, H. Fitness of drug-resistant malaria parasites. Acta Trop. 94, 251\u2013259 (2005).","journal-title":"Acta Trop."},{"key":"51994_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-270","volume":"11","author":"SL Croft","year":"2012","unstructured":"Croft, S. L. et al. Review of pyronaridine anti-malarial properties and product characteristics. Malar. J. 11, 270 (2012).","journal-title":"Malar. J."},{"key":"51994_CR37","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1021\/acsinfecdis.1c00262","volume":"7","author":"L Dembele","year":"2021","unstructured":"Dembele, L. et al. Ex vivo Plasmodium malariae culture method for antimalarial drugs screen in the field. ACS Infect. Dis. 7, 3025\u20133033 (2021).","journal-title":"ACS Infect. Dis."},{"key":"51994_CR38","doi-asserted-by":"crossref","unstructured":"Trager, W. & Jensen, J. B. Human malaria parasites in continuous culture. Science 193, 673\u2013675 (1976).","DOI":"10.1126\/science.781840"},{"key":"51994_CR39","doi-asserted-by":"publisher","first-page":"418","DOI":"10.2307\/3280287","volume":"65","author":"C Lambros","year":"1979","unstructured":"Lambros, C. & Vanderberg, J. P. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J. Parasitol. 65, 418 (1979).","journal-title":"J. Parasitol."},{"key":"51994_CR40","doi-asserted-by":"publisher","first-page":"997418","DOI":"10.3389\/fcimb.2022.997418","volume":"12","author":"LG Thiam","year":"2022","unstructured":"Thiam, L. G., Ansah, F., Niang, M., Awandare, G. A. & Aniweh, Y. Short-term cryopreservation and thawing have minimal effects on Plasmodium falciparum ex vivo invasion profile. Front. Cell. Infect. Microbiol. 12, 997418 (2022).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"51994_CR41","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/jac\/dkv488","volume":"71","author":"AF Mohamed","year":"2016","unstructured":"Mohamed, A. F. et al. Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK\/PD model. J. Antimicrob. Chemother. 71, 1279\u20131290 (2016).","journal-title":"J. Antimicrob. Chemother."},{"key":"51994_CR42","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/psp4.12197","volume":"6","author":"SG Wicha","year":"2017","unstructured":"Wicha, S. G., Huisinga, W. & Kloft, C. Translational pharmacometric evaluation of typical antibiotic broad-spectrum combination therapies against Staphylococcus aureus exploiting in vitro information. CPT Pharmacomet. Syst. Pharmacol. 6, 512\u2013522 (2017).","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"51994_CR43","doi-asserted-by":"publisher","first-page":"E37","DOI":"10.1111\/j.1469-0691.2011.03752.x","volume":"18","author":"JW Mouton","year":"2012","unstructured":"Mouton, J. W. et al. The role of pharmacokinetics\/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin. Microbiol. Infect. 18, E37\u2013E45 (2012).","journal-title":"Clin. Microbiol. Infect."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51994-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51994-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51994-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T09:05:13Z","timestamp":1725613513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51994-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["51994"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-51994-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,3]]},"assertion":[{"value":"15 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.D.G., C.O., P.C., and T.S. are employed by Ares Trading S.A., Switzerland, an affiliate of the healthcare business of Merck KGaA, Darmstadt, Germany. S.W. consultancy was funded by the healthcare business of Merck KGaA, Darmstadt, Germany. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7659"}}